Astellas Pharma Cash Flow - Quarterly (OTCMKTS:ALPMY)

Add to My Stocks
$17.95 $0.14 (0.79%) ALPMY stock closing price Sep 20, 2018 (Closing)

The Astellas Pharma cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. The profit-loss statement shows Astellas Pharma profits, the balance sheet shows Astellas Pharma debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. This statement can tell if a company is running out of money while still being profitable and is useful in Astellas Pharma stock analysis. Astellas Pharma had a positive net income cash flow of $593.35M till this quarter of 2019 Q1. This report is very useful in measuring the short term viability of a company. Astellas Pharma has a negative cash and cash equivalents change of $-202.31M.

View and download details of Astellas Pharma cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Apr - Mar2019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q4
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow147.94M583.76M430.35M289.91M143.96M570M436.86M308.61M148.52M574.26M
Net Increase (Decrease) in Assets Liabilities-372.53M-698.66M-683.24M-565.02M-450.27M-53M-797.51M-740.37M-706.87M-1.25B
Cash From (used in) Discontinued Operations----------
Other Adjustments Net-26.73M965.4M526.43M401.41M405.5M-929M-168.3M-231.68M-139.46M1.1B
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment84.82M-214.81M-169.15M-88.82M-20.15M-248M-188.51M-152.63M-64.49M-263.59M
Acquisition Disposition of Subsidiaires--753.5M-547.94M-554.1M-498.3M-455M-468.41M---354.01M
Increase (Decrease) in Investments-56.49M55.72M56.38M61.42M252M156.64M17.88M7.47M132.78M
Other Cash Inflow (Outflow) from Investment Activities-62.33M-184.35M-173.73M-67.45M-47.21M-204M-150.97M-60.24M-4.19M-735.67M
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares-255.63M-1.18B-629.33M-451.57M-6.37M-823M-429.31M-7.51M-7.11M-997.05M
Issuance (Repayment) of Debt Securities----------
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions-327.25M-644.7M-637.54M-315.94M-315.94M-626M-645.09M-333.2M-316.2M-577.8M
Other Cash from (used by) Financing Activities--9.74M-6.69M-5.33M-3.06M-34M-31.54M-7.63M-4.38M-31M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash15.41M30.78M109.89M92.52M55.63M-136M-62.29M-277.7M-226.68M-79.75M
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year3.05B3.07B3.22B3.29B3.56B2.57B2.69B2.14B--
Cash & Equivalents at Year End2.85B2.99B2.95B2.77B2.83B3.04B3.21B3.59B2.9B2.99B
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Astellas Pharma stock price history provides insight into historical stock price fluctuations, and Astellas Pharma stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • Net Change in Cash and Cash Equivalents: A positive net change in cash and cash equivalents shows that Astellas Pharma is able to meet its expenditure and grow cash at hand which demonstrates the financial strength of the company's balance sheet. Also see - Astellas Pharma stock price movement.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. Astellas Pharma gained $342.05M cash from operations. It is important to check this to see where the company is getting its money from.
  • Growth companies, typically most tech companies; spend heavily on investing activities and this figure stood at $22.5M for ALPMY stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $-582.26M for Astellas Pharma.

Key Financial Ratios For Astellas Pharma Cash Flow

FCF margin

Quarterly Cash Flow Statements For ASTELLAS PHARMA UNSP ADR EACH REPR 0.25 ORD Peers

Astrazeneca cash flow, Eisai cash flow, Pfizer cash flow, Shire cash flow, Zoetis cash flow